Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states.
研究设计
- 研究类型
- Case report
- 样本量
- 1
- 研究人群
- Single case report of a 54-year-old male experiencing maintenance insomnia, generalized anxiety, and panic symptoms associated with EPA-enriched fish oil supplement, and subsequently with montelukast (leukotriene receptor antagonist).
- 干预措施
- Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states. Fish oil supplement enriched in EPA (dose not specified); also montelukast (leukotriene receptor ant
- 对照组
- No treatment
- 主要结局
- Anxiety, panic symptoms, and maintenance insomnia associated with EPA-enriched fish oil and montelukast
- 效应方向
- Negative
- 偏倚风险
- High
摘要
We recently reported a case in which a 54-year-old male experienced maintenance insomnia, generalized anxiety and panic symptoms associated with consumption of a fish oil supplement enriched in eicosapentaenoic acid (EPA). We report here that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration. Since omega-3 fatty acids like EPA are precursors for the biosynthesis of eicosanoids including leukotrienes, a common factor to these psychiatric adverse events may be perturbations in this highly complex system of lipid inflammatory mediators.
简要概述
It is reported that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration.